Status:
UNKNOWN
Macrophage Programing in Acute Lung Injury
Lead Sponsor:
National Jewish Health
Conditions:
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
Brief Summary
The histologic hallmarks of lung inflammation and in the extreme, acute respiratory distress syndrome (ARDS), include intense accumulation of inflammatory cells in the airspaces and interstitium, inju...
Eligibility Criteria
Inclusion
- Written, informed consent (by surrogate if unconscious or if altered mental status)
- Admission to a Medical Intensive care unit
- Orally/nasally intubated, evaluable within 24 h of intubation or onset of ARDS
- Expected to remain mechanically ventilated for at least 48 h after the first study procedure.
Exclusion
- Treatment with immunosuppressants in the prior 3 months (antineoplastic agents, tumor necrosis factor alpha antagonists, cyclosporine, methotrexate, azathioprine, or mycophenolate. Treatment with glucocorticoids for septic shock is acceptable).
- History of solid organ or bone marrow transplantation
- History of chronic lung disease (e.g. COPD, pulmonary fibrosis, cystic fibrosis)
- Human immunodeficiency virus positivity
- Severe or massive hemoptysis
- At significant risk for bleeding (INR \> 3 or PTT \> 3x normal)
- Presence of an advanced directive to withhold life-sustaining treatment
- Morbid state or expected to survive less than 14 days because of an advanced co-morbid medical condition;
- Pregnancy
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03844893
Start Date
October 1 2019
End Date
March 1 2023
Last Update
August 22 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.